Stock Events

Stock Events

Rocket Pharmaceuticals 

$3.86
125
+$0.07+1.85% Friday 20:00
-$0.05-1.3%Friday 23:30After hours

Statistics

Day High
3.88
Day Low
3.86
52W High
5.45
52W Low
2.53
Volume
21,416
Avg. Volume
-
Mkt Cap
423.73M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.72
-0.12
0.48
1.08
Expected EPS
-0.4
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-223.12MNet Income

Analyst Ratings

11.67Average Price Target
The highest estimate is 15.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RCKT. It's not an investment recommendation.
NVIDIA
23
NVDA
Microsoft
19
MSFT
Amazon
19
AMZN
Alphabet
17
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is involved in gene editing, a direct competitor in the innovative gene therapy market where Rocket Pharmaceuticals operates.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine works on gene editing using CRISPR, competing in the gene therapy space alongside Rocket Pharmaceuticals.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is another key player in CRISPR gene editing, making it a competitor in the gene therapy field.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, overlapping with Rocket's focus areas.
Pfizer
PFE
Mkt Cap159.36B
Pfizer, with its broad interest in biopharmaceuticals, including gene therapy, competes on a larger scale across the same therapeutic areas as Rocket.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals engages in creating transformative medicines for serious diseases, including genetic therapies, competing with Rocket Pharmaceuticals.

About

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Show more...
CEO
Gaurav D. Shah
Employees
202
Country
United States
ISIN
US77313F1066
WKN
000A2JA9Q

Listings

MU
DE
9IP1.MU
STU
DE
9IP1.STU
F
DE
9IP1.F
XNAS
US
RCKT

0 Comments

Share your thoughts

FAQ

What is Rocket Pharmaceuticals stock price today?▼
The current price of RCKT is $3.86 USD — it has increased by +1.85% in the past 24 hours. Watch Rocket Pharmaceuticals stock price performance more closely on the chart.
What is Rocket Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Rocket Pharmaceuticals stocks are traded under the ticker RCKT.
Is Rocket Pharmaceuticals stock price growing?▼
RCKT stock has risen by +0% compared to the previous week, the month change is a +10.29% rise, over the last year Rocket Pharmaceuticals has showed a +17.68% increase.
What is Rocket Pharmaceuticals market cap?▼
Today Rocket Pharmaceuticals has the market capitalization of 423.73M
When is the next Rocket Pharmaceuticals earnings date?▼
Rocket Pharmaceuticals is going to release the next earnings report on November 05, 2026.
What were Rocket Pharmaceuticals earnings last quarter?▼
RCKT earnings for the last quarter are 1.08 USD per share, whereas the estimation was 0.86 USD resulting in a +25.58% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Rocket Pharmaceuticals revenue for the last year?▼
Rocket Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Rocket Pharmaceuticals net income for the last year?▼
RCKT net income for the last year is -223.12M USD.
How many employees does Rocket Pharmaceuticals have?▼
As of September 05, 2026, the company has 202 employees.
In which sector is Rocket Pharmaceuticals located?▼
Rocket Pharmaceuticals operates in the Health & Wellness sector.
When did Rocket Pharmaceuticals complete a stock split?▼
The last stock split for Rocket Pharmaceuticals was on January 05, 2018 with a ratio of 1:4.
Where is Rocket Pharmaceuticals headquartered?▼
Rocket Pharmaceuticals is headquartered in NEW YORK, United States.